Receptor-channel research at the interface between academia and pharma

Published on April 2, 2014   33 min
0:00
Hello, my name is Mihaly Hajos. I am from Yale School of Medicine. In my talk, I would like to give you an insight to drug discovery for neurological and psychiatric disorders. I will also focus on some challenges in neuropharmacology and how these obstacles could be addressed by collaborative efforts between academic and pharmaceutical research.
0:26
Use of mind-altering or psychoactive drugs, mostly plants or plant products, dates to prehistoric times. Archaeological findings demonstrated their use dating back at least 10,000 years. Some of these plants, for their active ingredients, are still used or abused today. And some even have found their way to clinical practice.
0:53
However, until very recently, mode of actions of these the mind-altering plants or substances have been totally unknown since it was only in the 20th century that we gained some insight to basic mechanisms of brain function. Nevertheless, artificial modification of mood or sensation by these plants clearly indicated that even the highest level of brain function can be altered, also providing hope for potential treatment of mental disorders. Eventually, a new scientific discipline was born, neuropharmacology, studying drug effects or neural function from molecular to behavioral responses.
1:42
In my talk I will discuss some very pragmatic aspects of neuropharmacology, and drug discovery, and the drug discovery process which is long, tedious, and expensive. I will give real-life examples in drug discovery from our work on alpha-7 nicotinic receptors. I will discuss interactions between academic and pharmaceutical research and some novel trends in this collaboration. However, first I will discuss drug target selection and summarize some fundamentals about drug receptor/ion channel interactions.
Hide

Receptor-channel research at the interface between academia and pharma

Embed in course/own notes